NCT03828942View on ClinicalTrials.gov

Monitoring the HeMAtological TOXicity of Drugs (HeMATOX)

CompletedOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

February 1, 2022

Study Completion Date

April 8, 2023

Conditions
Hematological AbnormalityHematotoxicity
Interventions
DRUG

drug inducing hematological toxicity

Drugs susceptible to induce hematological toxicities

Trial Locations (2)

67098

Rhumatology department, CHU Strasbourg, Hautepierre hospital, Strasbourg

75013

AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris

All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

Groupe Hospitalier Pitie-Salpetriere

OTHER

NCT03828942 - Monitoring the HeMAtological TOXicity of Drugs (HeMATOX) | Biotech Hunter | Biotech Hunter